SCHEMBL6070204

SCHEMBL6070204

CCOC(=O)c1c(C)nn(Cc2ccccc2)c1C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.76
POLB P06746 4/20 0.72
ALDH1A1 P00352 6/20 0.63
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
LMNA P02545 4/20 0.63
NPSR1 Q6W5P4 3/20 0.63
HTT P42858 2/20 0.63
HSD17B10 Q99714 2/20 0.63
KDM4E B2RXH2 1/20 0.63
MAPT P10636 1/20 0.63
PDE4D Q08499 1/20 0.63
NPC1 O15118 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
GAA P10253 3/20 0.60
HPGD P15428 2/20 0.60
TSHR P16473 3/20 0.59
TDP1 Q9NUW8 1/20 0.59
HBB P68871 2/20 0.58
ALOX15 P16050 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20551943 0.86 MAPK1 (1.00) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL19209447 0.85 MAPK1 (0.71) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL19209464 0.85 MAPK1 (0.60) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL8444618 0.84 POLB (1.00) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL3848644 0.83 MAPK1 (0.67) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL21333231 0.82 POLB (0.80) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL21332992 0.80 POLB (0.76) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL19207519 0.80 CYP19A1 (0.58) MAPK1POLBALDH1A1MEN1KMT2A
SCHEMBL22979354 0.79 PDE4D (0.55) MAPK1ALDH1A1MEN1KMT2ALMNA
SCHEMBL22125747 0.78 MAPK1 (0.62) MAPK1POLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236412-A1 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION 2003-12-25 US claimed
US-7087634-B2 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION (US) 2006-08-08 US disclosed
US-20030236412-A1 Cyclic AMP-specific phosphodiesterase inhibitors ICOS CORPORATION 2003-12-25 US disclosed
US-6569885-B1 Such as 1-(4-bromophenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester; side effect reduction; for treatment of central nervous system disorders ICOS CORPORATION 2003-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236412-A1 Cyclic AMP-specific phosphodiesterase inhibitors PDE4A, PDE4B, PDE7A MAPK1 1130/4885POLB 1852/4885ALDH1A1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.